GSK plc has completed the acquisition of 35Pharma Inc. for $950 million on April 15, 2026; this acquisition enhances GSK’s portfolio with HS235, a promising treatment for pulmonary hypertension. The global market for pulmonary hypertension therapies is expected to reach $18 billion by 2032, where HS235 may play a significant role.